Acute Lymphoblastic Leukemia (ALL) — Deal Benchmarks & Valuation
Market Analysis
Acute Lymphoblastic Leukemia (ALL) is one of the most actively transacted indications in oncology licensing. Phase 1 deals for acute lymphoblastic leukemia (all) carry a median total deal value of $1.0B, with upfront payments ranging from $48M to $158M. The recommended deal structure allocates approximately 10% to upfront payments and 90% to milestones.
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Customize these benchmarks for your asset
Adjust phase, modality, competitive position, and 10+ other parameters.
Frequently Asked Questions
What are typical deal terms for acute lymphoblastic leukemia (all) licensing?
Full Benchmark Analysis
Complete deal term ranges, comparable transactions, and negotiation insights.
We'll email you the full benchmark data for this page. No spam, unsubscribe anytime.
7-day money-back guarantee · Cancel anytime
Ready to Calculate Your Deal Terms?
Get instant, customized benchmarks based on real market data from 600+ biopharma licensing deals.
Start Calculating